Physician profile
Robert H Sherrin
NPI 1396729059
$747.37
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $42.33 · 2021: $139 · 2022: $36.81 · 2023: $306 · 2024: $31.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279.50 | 2023-2024 | Durysta, Lumigan, Alphagan P |
| Sun Pharmaceutical Industries INC. | $104.17 | 2019-2022 | |
| Alcon Vision LLC | $66.85 | 2019-2023 | Clareon |
| Aerie Pharmaceuticals, INC. | $61.46 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $36.73 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $35.92 | 2021 | |
| Sight Sciences, INC. | $35.21 | 2023 | Tearcare System |
| Dompe US, INC. | $23.09 | 2021 | |
| Shire North American Group INC | $20.29 | 2019 | |
| Eyevance Pharmaceuticals LLC | $20.04 | 2019 | |
| Alcon Research LLC | $18.44 | 2019 | |
| Eyepoint US, INC. | $17.82 | 2019 | |
| Biotissue Holdings INC. | $15.65 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sherrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.